Granules India Limited (GRANULES) Financial History

Name: Granules India Limited (GRANULES) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-09-20

Granules India Limited (GRANULES) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Hyderabad, India with about 4,306 employees. Its market capitalization is roughly ₹239 billion. In the fiscal year ended 2026-03-31, GRANULES reported ₹53.4B in revenue and ₹6.0B in net income.

Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), finished dosages (FDs), and peptides CDMO in India and internationally.

Interactive charts & full statements →

GRANULES Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	₹53.4B	₹44.6B	₹44.9B	₹45.0B	—
Gross Profit	₹33.2B	₹26.2B	₹23.6B	₹21.1B	—
Operating Income (EBIT)	₹9.0B	₹7.3B	₹6.6B	₹7.4B	—
Net Income	₹6.0B	₹5.0B	₹4.1B	₹5.2B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GRANULES Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total Revenue	₹14.6B	₹14.6B	₹13.8B	₹12.9B	₹12.1B
Gross Profit	₹9.6B	₹9.5B	₹8.8B	₹8.5B	₹7.8B
Operating Income (EBIT)	₹2.6B	₹2.7B	₹2.3B	₹2.1B	₹1.8B
Net Income	₹1.8B	₹2.0B	₹1.5B	₹1.3B	₹1.1B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GRANULES Free Cash Flow History

Cash flow	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Dividends Paid	(₹364M)	(₹364M)	(₹363M)	(₹186M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GRANULES Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹77.2B	₹62.5B	₹55.2B	₹49.0B	—
Total Liabilities	₹26.3B	₹25.4B	₹23.0B	₹20.7B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive GRANULES viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

1276 · Jiangsu Hengrui Pharmaceuticals Co.,Ltd — HK$307 billion
NEULANDLAB · Neuland Laboratories Limited — ₹293 billion
4540 · Tsumura & Co. — JPY 287 billion
PPLPHARMA · Piramal Pharma Limited — ₹276 billion
4516 · Nippon Shinyaku Co., Ltd. — JPY 233 billion
CAPLIPOINT · Caplin Point Laboratories Limited — ₹209 billion
3692 · Hansoh Pharmaceutical Group Company Limited — HK$208 billion
SHILPAMED · Shilpa Medicare Limited — ₹200 billion

← GRANDOAK All “G” companies GRAPHITE →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.